
Eli Lilly Cuts Price of Weight Loss, Diabetes Drug Zepbound
Pharmaceutical giant Eli Lilly announced on Aug. 27 that it is selling its weight loss and diabetes drug Zepbound in single-dose vials at around half the cost of some of its original doses. In a press release, Eli Lilly said the move is part of ongoing efforts to significantly boost drug supply amid heightened demand. The company said the single-dose vials will contain 2.5-milligram and 5-milligram formulations of Zepbound, a form of tirzepatide, and patients will need to inject themselves. They will be available only for self-pay for patients with an on-label prescription. Under the new pricing plan, a one-month supply of the 2.5 mg Zepbound single-dose vial will cost $399, or $99.75 per vial, while a four-week supply of the 5 mg dose is $549, or $137.25 per vial, the Indianapolis-headquartered firm said....
